Domain Therapeutics
Records under this name other than the patents Domain Therapeutics holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Showing 1 to 6 of 6 · Back to Domain Therapeutics
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,029,393 | Adenosine receptor ligands and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,453,647 | Benzimidazole Derivatives as Adenosine Receptor Antagonists Lapsed on the fee record Ended Sep 27, 2026 · High confidence | Lapsed on the fee record | Ended Sep 27, 2026 | High confidence |
| US 11,008,323 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors Lapsed on the fee record Ended May 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 18, 2025 | From the USPTO record |
| US 10,221,179 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors Lapsed on the fee record Ended Mar 5, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 5, 2023 | From the USPTO record |
| US 8,962,627 | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors Formerly held Lapsed on the fee record Ended Feb 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 24, 2023 | From the USPTO record |
| US 9,434,734 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors Lapsed on the fee record Ended Sep 6, 2020 · From the USPTO record | Lapsed on the fee record | Ended Sep 6, 2020 | From the USPTO record |